JP2010524937A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524937A5
JP2010524937A5 JP2010504069A JP2010504069A JP2010524937A5 JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5 JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5
Authority
JP
Japan
Prior art keywords
cancer
methyl
composition
pharmaceutically acceptable
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504069A
Other languages
English (en)
Japanese (ja)
Other versions
JP5498936B2 (ja
JP2010524937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/004862 external-priority patent/WO2008130552A1/en
Publication of JP2010524937A publication Critical patent/JP2010524937A/ja
Publication of JP2010524937A5 publication Critical patent/JP2010524937A5/ja
Application granted granted Critical
Publication of JP5498936B2 publication Critical patent/JP5498936B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504069A 2007-04-18 2008-04-15 Smoアンタゴニストであるトリアゾール誘導体 Active JP5498936B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18
US60/925,018 2007-04-18
PCT/US2008/004862 WO2008130552A1 (en) 2007-04-18 2008-04-15 Triazole derivatives which are smo antagonists

Publications (3)

Publication Number Publication Date
JP2010524937A JP2010524937A (ja) 2010-07-22
JP2010524937A5 true JP2010524937A5 (enExample) 2011-05-19
JP5498936B2 JP5498936B2 (ja) 2014-05-21

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504069A Active JP5498936B2 (ja) 2007-04-18 2008-04-15 Smoアンタゴニストであるトリアゾール誘導体

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
ES2610130T3 (es) 2007-12-27 2017-04-26 Infinity Pharmaceuticals, Inc. Métodos para reducción estereoselectiva
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
WO2010023480A1 (en) * 2008-08-29 2010-03-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Saturated bicyclic heterocyclic derivatives as smo antagonists
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3,3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2004243301B2 (en) 2003-05-29 2010-03-25 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
AU2005325267B2 (en) 2004-04-30 2010-11-04 Curis Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
WO2006017542A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
EP2316832B1 (en) 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
NZ555419A (en) 2004-11-03 2009-07-31 Curis Inc Mediators of the hedgehog gene signaling pathways, compositions and uses related thereto
JP5036722B2 (ja) 2005-10-20 2012-09-26 メルク・シャープ・エンド・ドーム・コーポレイション 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1阻害剤としてのトリアゾール誘導体

Similar Documents

Publication Publication Date Title
JP2010524937A5 (enExample)
US9205086B2 (en) Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP2008516982A5 (enExample)
JP2011502958A5 (enExample)
US20130156755A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
JP2009538897A5 (enExample)
JP2017505762A5 (enExample)
JP2013516393A5 (enExample)
JP2008535902A5 (enExample)
US20130171105A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
JP2014533299A5 (enExample)
JPWO2023099624A5 (enExample)
JP2015531366A5 (enExample)
JP2014526500A5 (enExample)
JP2011517457A5 (enExample)
JP2009534386A5 (enExample)
JP2013537229A5 (enExample)
JP2011504903A5 (enExample)
RU2008140940A (ru) Производное триазола или его соль
JP2008526723A5 (enExample)
JP2012533546A5 (enExample)
JP2010526814A5 (enExample)
JP2005500311A5 (enExample)
JP2009526034A5 (enExample)
JP2009536196A5 (enExample)